

<b>NCT ID</b>	NCT03400332
<b>Title</b>	A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2018-01-17
<b>Location</b>	Arkansas, United States California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	BMS-986253, Ipilimumab, Nivolumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03217747
<b>Title</b>	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2017-07-14
<b>Location</b>	Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05141721
<b>Title</b>	A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-12-02

<b>Location</b>	Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03530397
<b>Title</b>	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-05-21
<b>Location</b>	Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03783403
<b>Title</b>	A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-12-21

<b>Location</b>	Alabama, United States Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	CC-95251, cetuximab, Rituximab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT01061515
<b>Title</b>	Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2010-02-03
<b>Location</b>	Missouri, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03981146
<b>Title</b>	A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-06-10
<b>Location</b>	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Nivolumab, Opdivo
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04973163
<b>Title</b>	A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
<b>Phase</b>	Phase 1
<b>Date Added</b>	2021-07-22

<b>Location</b>	Texas, United States Belgium Spain United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	BI 1701963, BI 1823911, Midazolam
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05205330
<b>Title</b>	A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2022-01-25
<b>Location</b>	Italy
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	AGEN2034, Balstilimab, CR6086
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03313778
<b>Title</b>	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-10-18
<b>Location</b>	District of Columbia, United States Florida, United States Massachusetts, United States New York, United States Ohio, United States Pennsylvania, United States Australia Japan United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	mRNA-4157, Pembrolizumab, Keytruda
<b>Tags</b>	MSS/ MMRp